Literature DB >> 25425199

The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

T Barbui1, J Thiele2, A Carobbio1, A M Vannucchi3, A Tefferi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25425199     DOI： 10.1038/leu.2014.328

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Masked polycythemia vera (mPV): results of an international study.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Guido Finazzi; Alessandra Carobbio; Elisa Rumi; Maria Luigia Randi; Irene Bertozzi; Alessandro M Vannucchi; Lisa Pieri; Valentina Carrai; Bettina Gisslinger; Leonhard Müllauer; Marco Ruggeri; Alessandro Rambaldi; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-09-19       Impact factor: 10.047

2.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

3.  Calreticulin mutations and long-term survival in essential thrombocythemia.

Authors:  A Tefferi; E A Wassie; T L Lasho; C Finke; A A Belachew; R P Ketterling; C A Hanson; A Pardanani; N Gangat; A P Wolanskyj
Journal:  Leukemia       Date:  2014-05-05       Impact factor: 11.528

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

7.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Authors:  Francesco Passamonti; Elisa Rumi; Ester Pungolino; Lucia Malabarba; Paola Bertazzoni; Marina Valentini; Ester Orlandi; Luca Arcaini; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Am J Med       Date:  2004-11-15       Impact factor: 4.965

Review 8.  Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Authors:  G Barosi; A Tefferi; C Besses; G Birgegard; F Cervantes; G Finazzi; H Gisslinger; M Griesshammer; C Harrison; R Hehlmann; S Hermouet; J-J Kiladjian; N Kröger; R Mesa; M F Mc Mullin; A Pardanani; F Passamonti; J Samuelsson; A M Vannucchi; A Reiter; R T Silver; S Verstovsek; G Tognoni; T Barbui
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  4 in total

Review 1.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 2.  Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.

Authors:  Hannah Goulart; John Mascarenhas; Douglas Tremblay
Journal:  Ann Hematol       Date:  2022-03-28       Impact factor: 3.673

Review 3.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

Review 4.  Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.

Authors:  Julian Baumeister; Nicolas Chatain; Alexandros Marios Sofias; Twan Lammers; Steffen Koschmieder
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.